Fabien Depis
Founder & Chief Executive Officer TregShield Bio
Seminars
Tuesday 24th March 2026
Roundtable Discussion: Engineering Next-Generation Tregs to Advance Treg Therapeutic Development
1:15 pm
- Investigating engineering Treg cells from CD4+ and iPSC precursors to understand the impact on efficacy
- Examining engineering strategies required to achieve durable Treg stability in vivo for long-term efficacy
- Engineering CAR-Tregs and Allogeneic Tregs for potential therapies of autoimmune and transplant disease
- Growth factor and durability support strategies for long term Treg persistence in patients
Wednesday 25th March 2026
Panel Discussion: Evaluating Changing FDA & GMP Expectations to Overcome Regulatory Challenges & Accelerate Clinical Approval
2:30 pm
- Understand how Treg GMP and approval processes have evolved for 2026
- Sharing FDA interactions to reveal and combat manufacturing and regulatory approval challenges
- Identifying opportunities for accelerated regulatory progression amid regulatory changes
